Important note: Information in this article was accurate in November 2003. The state of the art may have changed since the publication date.
 |
HIV Treatment Bulletin - November 2003
Polly Clayden, HIV i-Base
The Generic Anti-Retroviral Procurement Project (GARPP) and the Treatment Action Campaign (TAC) Treatment Project have requested permission from the originator company Boehringer Ingelheim for the right to import generic nevirapine to South Africa. Refusal to grant this voluntary licence will lead GARPP and the TAC to apply to the Commissioner of Patents for compulsory licenses through the courts.
This request, made on 26 September, follows previous attempts from the TAC and Medicins sans Frontieres South Africa to obtain voluntary licences for nevirapine since 1999.
The Medicines Control Council (MCC) has already licensed generic nevirapine for use in South Africa and it can be purchased for just over R70.00 per month, compared to R410.00 for a month’s supply of Boehringer’s Viramune. But without Boehringer’s permission importing generic nevirapine remains illegal.
Additionally the TAC and GARPP stress that Boehringer’s exclusive licence prevents access to new co-formulated antiretroviral pills that can make combination therapy as simple as two pills a day
031110
IB30409-13
©2003. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
